AR087607A1 - Derivados de piridazinona - Google Patents
Derivados de piridazinonaInfo
- Publication number
- AR087607A1 AR087607A1 ARP120103061A ARP120103061A AR087607A1 AR 087607 A1 AR087607 A1 AR 087607A1 AR P120103061 A ARP120103061 A AR P120103061A AR P120103061 A ARP120103061 A AR P120103061A AR 087607 A1 AR087607 A1 AR 087607A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- hydrogen atom
- haloalkyl
- independently
- Prior art date
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 abstract 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 125000006661 (C4-C6) heterocyclic group Chemical group 0.000 abstract 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 125000004981 cycloalkylmethyl group Chemical group 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 229910052731 fluorine Chemical group 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
- C07D237/16—Two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/18—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/22—Nitrogen and oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Los procesos para su preparación, las composiciones farmacéuticas que los contienen y su uso en terapia. Reivindicación 1: Un compuesto de fórmula (1) donde R¹ representa un átomo de hidrógeno o de flúor o un grupo trifluorometilo; R² representa un grupo -X-Y-R³; X e Y representan cada uno independientemente un enlace, un átomo de oxígeno o un grupo -C(O), -S(O)ₙ, -C(O)NR⁴, -S(O)₂NR⁴, -NR⁴, un resto de fórmula (2) ó (3), o -CR⁴R⁵-, siempre que X e Y no puedan ambos representar simultáneamente un enlace y siempre que si X e Y son ambos distintos a un enlace, entonces al menos uno de X e Y represente -CR⁴R⁵-; n es 0, 1 ó 2; cada R⁴ representa independientemente un átomo de hidrógeno o un grupo alquilo C₁₋₆ ó haloalquilo C₁₋₆; cada R⁵ representa independientemente un átomo de hidrógeno, un grupo alquilo C₁₋₆ ó haloalquilo C₁₋₆ ó =CH-; R³ representa un sistema de anillo carbocíclico o heterocíclico saturado o insaturado de 3 a 10 miembros, el sistema de anillo en sí mismo está opcionalmente sustituido por al menos un sustituyente seleccionado de halógeno, hidroxilo, ciano, oxo, alquilo C₁₋₆, alquenilo C₂₋₆, haloalquilo C₁₋₆, hidroxialquilo C₁₋₆, alcoxi C₁₋₆, haloalcoxi C₁₋₆, alquiltio C₁₋₆, alquilsulfinilo C₁₋₆, alquilsulfonilo C₁₋₆, alquilcarbonilo C₁₋₆, alquilcarboniloxi C₁₋₆, alcoxicarbonilo C₁₋₆, amino (-NH₂), -CON(R⁶)₂, alquilamino C₁₋₆, dialquilamino C₁₋₆, cicloalquilo C₃₋₆, cicloalquiloxi C₃₋₆, cicloalquilmetilo C₃₋₆, -[O]ₚ-(CH₂)q-O-R⁷ y un anillo heterocíclico saturado o insaturado de 4 a 6 miembros (sustituido opcionalmente con al menos un sustituyente seleccionado de alquilo C₁₋₄ y alcoxi C₁₋₄); cada R⁶ representa independientemente un átomo de hidrógeno o un grupo alquilo C₁₋₆; p es 0 ó 1; q es 1, 2, 3 ó 4; y R⁷ representa un grupo alquilo C₁₋₆; o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1114399.7A GB201114399D0 (en) | 2011-08-22 | 2011-08-22 | Novel compounds |
| GB201118658A GB201118658D0 (en) | 2011-10-27 | 2011-10-27 | Novel compounds |
| GBGB1203533.3A GB201203533D0 (en) | 2012-02-29 | 2012-02-29 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR087607A1 true AR087607A1 (es) | 2014-04-03 |
Family
ID=46758786
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120103061A AR087607A1 (es) | 2011-08-22 | 2012-08-21 | Derivados de piridazinona |
| ARP220102738A AR127309A2 (es) | 2011-08-22 | 2022-10-06 | Derivados de piridazinona |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102738A AR127309A2 (es) | 2011-08-22 | 2022-10-06 | Derivados de piridazinona |
Country Status (38)
| Country | Link |
|---|---|
| US (6) | US9290456B2 (es) |
| EP (1) | EP2748149B9 (es) |
| JP (1) | JP6022573B2 (es) |
| KR (1) | KR101961851B1 (es) |
| CN (1) | CN103748079B (es) |
| AP (1) | AP2014007512A0 (es) |
| AR (2) | AR087607A1 (es) |
| AU (1) | AU2012298335B2 (es) |
| BR (1) | BR112014003906B1 (es) |
| CA (1) | CA2846204C (es) |
| CL (1) | CL2014000395A1 (es) |
| CO (1) | CO6910197A2 (es) |
| CR (1) | CR20140133A (es) |
| CY (1) | CY1117105T1 (es) |
| DK (1) | DK2748149T5 (es) |
| DO (1) | DOP2014000036A (es) |
| EA (1) | EA024956B1 (es) |
| EC (1) | ECSP14013215A (es) |
| ES (1) | ES2559631T3 (es) |
| GE (1) | GEP20156372B (es) |
| HK (1) | HK1194072A1 (es) |
| HR (1) | HRP20151310T2 (es) |
| HU (1) | HUE026691T2 (es) |
| IL (1) | IL230143A (es) |
| JO (1) | JO3115B1 (es) |
| ME (1) | ME02319B (es) |
| MX (1) | MX2014000783A (es) |
| MY (1) | MY180618A (es) |
| PE (1) | PE20141208A1 (es) |
| PL (1) | PL2748149T3 (es) |
| PT (1) | PT2748149E (es) |
| RS (1) | RS54515B9 (es) |
| SI (1) | SI2748149T1 (es) |
| SM (1) | SMT201600023B (es) |
| TW (1) | TWI546289B (es) |
| UY (1) | UY34280A (es) |
| WO (1) | WO2013027000A1 (es) |
| ZA (1) | ZA201400153B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8969353B2 (en) | 2008-11-07 | 2015-03-03 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
| GB201111705D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Compounds and their use |
| GB201111704D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Novel compounds |
| JO3115B1 (ar) * | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | مركبات بيريدازينون واستخدامها كمثبطات daao |
| EA032088B1 (ru) | 2011-10-27 | 2019-04-30 | Массачусетс Инститьют Оф Текнолоджи | Аминокислотные производные, функционализованные на n-конце, способные образовывать микросферы, инкапсулирующие лекарственное средство |
| PE20141361A1 (es) * | 2011-11-15 | 2014-10-13 | Takeda Pharmaceutical | Compuesto heterociclico dihidroxi aromatico |
| WO2014025993A1 (en) | 2012-08-08 | 2014-02-13 | The Johns Hopkins University | Inhibitors of d-amino acid oxidase |
| GB201222711D0 (en) * | 2012-12-17 | 2013-01-30 | Takeda Pharmaceutical | Novel compounds |
| US9956113B2 (en) | 2013-03-12 | 2018-05-01 | The Board Of Trustees Of The Leland Stanford Junior University | Method and system for regulating core body temperature |
| GB201403944D0 (en) * | 2014-03-06 | 2014-04-23 | Takeda Pharmaceutical | New use |
| CN112773798B (zh) * | 2014-04-30 | 2024-03-29 | 宇凤·简·曾 | 作为d-氨基酸氧化酶抑制剂的已知化合物的用途 |
| EP3310764B1 (en) | 2015-06-19 | 2023-04-19 | Massachusetts Institute of Technology | Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell |
| WO2019043635A1 (en) | 2017-09-01 | 2019-03-07 | Richter Gedeon Nyrt. | COMPOUNDS INHIBITING THE ACTIVITY OF D-AMINO ACID OXIDASE |
| US10336724B2 (en) * | 2017-10-18 | 2019-07-02 | Syneurx International (Taiwan) Corp. | D-amino acid oxidase inhibitors and therapeutic uses thereof |
| CN109725092A (zh) * | 2019-03-19 | 2019-05-07 | 北京和合医学诊断技术股份有限公司 | 检测血液中齐拉西酮含量的液相色谱分析方法 |
| JP2021138648A (ja) | 2020-03-04 | 2021-09-16 | 武田薬品工業株式会社 | 経口固形製剤 |
| WO2022187127A1 (en) | 2021-03-01 | 2022-09-09 | Takeda Pharmaceutical Company Limited | Use of luvadaxistat for the treatment of cognitive impairment |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH636632A5 (de) | 1976-10-08 | 1983-06-15 | Ciba Geigy Ag | Neues verfahren zur herstellung von schwermetallkomplexen. |
| LU75958A1 (es) | 1976-10-08 | 1978-05-16 | ||
| GB2025416A (en) | 1978-07-14 | 1980-01-23 | Pfizer Ltd | Mercaptopyridazinethione antifungal agents |
| GB8421427D0 (en) | 1984-08-23 | 1984-09-26 | Smith Kline French Lab | Chemical compounds |
| EG18314A (en) | 1985-09-26 | 1993-02-28 | Squibb & Sons Inc | Process for preparing of 2-oxo-1((substituted sulfonyl)amino)carbonyl)-azitidines |
| US4743685A (en) | 1985-09-26 | 1988-05-10 | E. R. Squibb & Sons, Inc. | 2-oxo-1-[[(substituted sulfonyl)amino]carbonyl]azetidines |
| DK170088A (da) | 1987-04-10 | 1988-10-11 | Hoffmann La Roche | Acylderivater |
| WO1989000423A1 (en) | 1987-07-09 | 1989-01-26 | Pfizer Inc. | 2-amino-5-hydroxy-4-pyrimidones |
| JPH01202875A (ja) | 1988-02-09 | 1989-08-15 | Fujitsu Ltd | 超伝導材料構造の製造方法 |
| US5244890A (en) | 1988-06-06 | 1993-09-14 | Fujisawa Pharmaceutical Co., Ltd. | Cephem compounds |
| DK0489515T3 (da) | 1990-11-22 | 1995-11-06 | Cerestar Holding Bv | Fremgangsmåde til fremstilling af chokolade |
| EP0544166A3 (en) | 1991-11-26 | 1993-11-03 | Hoffmann La Roche | Cephalosporinderivatives |
| GB9219313D0 (en) | 1992-09-11 | 1992-10-28 | Kodak Ltd | Method of forming a photographic colour image |
| WO1995011235A1 (en) | 1993-10-20 | 1995-04-27 | The Upjohn Company | Pyrimidinones as antiarthritic and anti-inflammatories |
| CA2196995C (en) | 1994-08-24 | 2008-05-13 | Michael Balestra | Spiro-azabicyclic compounds useful in therapy |
| JPH092534A (ja) | 1995-06-16 | 1997-01-07 | Terada Seisakusho:Kk | 茶貯蔵容器 |
| JPH0925234A (ja) | 1995-07-12 | 1997-01-28 | Wakunaga Pharmaceut Co Ltd | 脳疾患改善剤 |
| SE9504661D0 (sv) | 1995-12-22 | 1995-12-22 | Astra Pharma Inc | New compounds |
| SE9600683D0 (sv) | 1996-02-23 | 1996-02-23 | Astra Ab | Azabicyclic esters of carbamic acids useful in therapy |
| AR013184A1 (es) | 1997-07-18 | 2000-12-13 | Astrazeneca Ab | Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis |
| SE9702799D0 (sv) | 1997-07-25 | 1997-07-25 | Astra Ab | New compounds |
| US6525053B1 (en) | 1997-08-22 | 2003-02-25 | Abbott Laboratories | Prostaglandin endoperoxide H synthase biosynthesis inhibitors |
| BR9812127A (pt) | 1997-08-22 | 2000-07-18 | Abbott Lab | Arilpiridazinonas como inibidores da biossìntese de prostagleina endoperóxido h sintase |
| US6440965B1 (en) | 1997-10-15 | 2002-08-27 | Krenitsky Pharmaceuticals, Inc. | Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system |
| ES2262322T3 (es) | 1998-06-10 | 2006-11-16 | Meiji Seika Kaisha, Ltd. | Tratamiento de la degenaracion espinocereberal y comoposiciones utiles para el tratamiento de degeneracion espinocerebelar. |
| KR100666838B1 (ko) | 1998-10-27 | 2007-01-11 | 아보트 러보러터리즈 | 프로스타글란딘 엔도퍼옥사이드 ｈ 신타제 생합성 억제제 및 이를 포함하는 약제학적 조성물 |
| SE9900100D0 (sv) | 1999-01-15 | 1999-01-15 | Astra Ab | New compounds |
| SE9903760D0 (sv) | 1999-10-18 | 1999-10-18 | Astra Ab | New compounds |
| SE9904176D0 (sv) | 1999-11-18 | 1999-11-18 | Astra Ab | New use |
| SE0000540D0 (sv) | 2000-02-18 | 2000-02-18 | Astrazeneca Ab | New compounds |
| JP2002028187A (ja) | 2000-07-14 | 2002-01-29 | Toto Ltd | 車いす |
| SE0002729D0 (sv) | 2000-07-20 | 2000-07-20 | Astrazeneca Ab | Novel compound form |
| US7179912B2 (en) | 2000-09-01 | 2007-02-20 | Icos Corporation | Materials and methods to potentiate cancer treatment |
| CN101486683B (zh) * | 2000-09-18 | 2011-12-21 | 卫材R&D管理有限公司 | 哒嗪酮和三嗪酮化合物及其作为药物制剂的用途 |
| DK1357111T3 (da) | 2000-12-28 | 2009-11-02 | Shionogi & Co | 2-pyridonderivater med affinitet for cannabinoid type 2-receptor |
| JP4549024B2 (ja) | 2001-05-18 | 2010-09-22 | アストラゼネカ・アクチエボラーグ | ４（フェニル−ピペラジニル−メチル）ベンズアミド誘導体及び疼痛、不安症又は胃腸障害の治療のためのその使用 |
| NZ529426A (en) | 2001-06-01 | 2005-07-29 | Astrazeneca Ab | Spiroazabicyclic heterocyclic amine ligands for nicotinic acetylcholine receptors useful in therapy |
| WO2003047558A2 (en) | 2001-12-03 | 2003-06-12 | Genset S.A. | Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors |
| SI1466912T1 (sl) | 2002-01-18 | 2013-08-30 | Astellas Pharma Inc. | Derivat 2-acilaminotiazola ali njegova sol |
| KR20040099446A (ko) | 2002-04-18 | 2004-11-26 | 아스트라제네카 아베 | 헤테로시클릭 화합물 |
| NZ561794A (en) | 2002-04-18 | 2008-11-28 | Astrazeneca Ab | Furyl spiroazabicyclic heterocyclic amines as nicotinic acetylcholine agonists |
| AU2003224545B2 (en) | 2002-04-18 | 2009-08-13 | Astrazeneca Ab | Thienyl compounds |
| US20040082627A1 (en) | 2002-06-21 | 2004-04-29 | Darrow James W. | Certain aromatic monocycles as kinase modulators |
| SE0202430D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | New Compounds |
| SE0202465D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | New compounds |
| SE0202598D0 (sv) | 2002-09-02 | 2002-09-02 | Astrazeneca Ab | Alpha-7 Nicotinic receptor agonists and statins in combination |
| BRPI0409649A (pt) | 2003-04-23 | 2006-04-25 | Pharmacia & Upjohn Co Llc | pirimidinonas e pirimidinotionas substituìdas como antagonistas de crf |
| US7517994B2 (en) | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| AU2004293018B2 (en) | 2003-11-19 | 2010-02-18 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| MY141255A (en) | 2003-12-11 | 2010-03-31 | Memory Pharm Corp | Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs |
| PL380887A1 (pl) | 2003-12-29 | 2007-04-02 | Sepracor Inc. | Pirolowe i pirazolowe inhibitory DAAO |
| US7915424B2 (en) | 2004-03-22 | 2011-03-29 | Eli Lilly And Company | Pyridyl derivatives and their use as mGlu5 antagonists |
| AU2006257863A1 (en) | 2005-06-10 | 2006-12-21 | F. Hoffmann-La Roche Ag | Trisubstituted amines as phosphodiesterase 4 inhibitors |
| TWI375669B (en) | 2006-03-17 | 2012-11-01 | Sumitomo Chemical Co | Pyridazinone compound and use thereof |
| WO2008005456A2 (en) * | 2006-06-30 | 2008-01-10 | Sepracor Inc. | Fused heterocyclic inhibitors of d-amino acid oxidase |
| US7579370B2 (en) | 2006-06-30 | 2009-08-25 | Sepracor Inc. | Fused heterocycles |
| WO2008089453A2 (en) | 2007-01-18 | 2008-07-24 | Sepracor Inc. | Inhibitors of d-amino acid oxidase |
| AR064962A1 (es) | 2007-01-22 | 2009-05-06 | Syngenta Participations Ag | Derivados de piridazina utiles como fungicidas |
| JP5147866B2 (ja) * | 2007-03-15 | 2013-02-20 | メルク・シャープ・アンド・ドーム・コーポレーション | グルカン合成酵素阻害剤として有用であるピリダジノン誘導体 |
| MX2009010407A (es) | 2007-03-28 | 2009-12-01 | Apotex Technologies Inc | Derivados fluorados de deferiprona. |
| WO2008156607A1 (en) * | 2007-06-12 | 2008-12-24 | Neurogen Corporation | Substituted pyrimidinones |
| JP2009002534A (ja) | 2007-06-19 | 2009-01-08 | Denso Corp | 熱交換器 |
| EP2328586A2 (en) | 2008-05-20 | 2011-06-08 | Cephalon, Inc. | Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands |
| WO2010017418A1 (en) | 2008-08-07 | 2010-02-11 | Sepracor Inc. | Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase |
| WO2010058314A1 (en) * | 2008-11-18 | 2010-05-27 | Pfizer Inc. | Hydroxyquinolin-2(1h)-ones and derivatives thereof |
| HUE027478T2 (en) | 2009-02-05 | 2016-09-28 | Takeda Pharmaceuticals Co | Pyridazinone Compounds |
| US20130065857A1 (en) | 2009-10-12 | 2013-03-14 | Baylor College Of Medicine | Novel dxr inhibitors for antimicrobial therapy |
| BR112012021656A2 (pt) | 2010-03-04 | 2017-02-07 | Merck Sharp & Dohme | composto, uso do mesmo, e, composição farmacêutica |
| EP2542076B1 (en) | 2010-03-04 | 2021-01-13 | Merck Sharp & Dohme Corp. | Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders |
| MX2012010188A (es) | 2010-03-04 | 2012-10-03 | Merck Sharp & Dohme | Inhibidores de catecol o-metil transferasa y su uso en el tratamiento de transtornos psicoticos. |
| US20120046232A1 (en) | 2010-06-22 | 2012-02-23 | Medical University Of South Carolina | Compositions and methods for reducing relapse of addictive behavior |
| AU2012275499A1 (en) | 2011-06-27 | 2013-12-19 | Kyorin Pharmaceutical Co., Ltd. | Bridged bicyclic compounds for the treatment of bacterial infections |
| GB201111704D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Novel compounds |
| GB201111705D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Compounds and their use |
| JO3115B1 (ar) | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | مركبات بيريدازينون واستخدامها كمثبطات daao |
| PE20141361A1 (es) | 2011-11-15 | 2014-10-13 | Takeda Pharmaceutical | Compuesto heterociclico dihidroxi aromatico |
| US8868710B2 (en) | 2011-11-18 | 2014-10-21 | Amazon Technologies, Inc. | Virtual network interface objects |
| GB201222711D0 (en) | 2012-12-17 | 2013-01-30 | Takeda Pharmaceutical | Novel compounds |
-
2012
- 2012-08-15 JO JOP/2012/0232A patent/JO3115B1/ar active
- 2012-08-21 TW TW101130241A patent/TWI546289B/zh active
- 2012-08-21 PE PE2014000238A patent/PE20141208A1/es active IP Right Grant
- 2012-08-21 RS RS20160010A patent/RS54515B9/sr unknown
- 2012-08-21 HU HUE12753164A patent/HUE026691T2/hu unknown
- 2012-08-21 CA CA2846204A patent/CA2846204C/en active Active
- 2012-08-21 GE GEAP201213407A patent/GEP20156372B/en unknown
- 2012-08-21 EP EP12753164.8A patent/EP2748149B9/en active Active
- 2012-08-21 UY UY0001034280A patent/UY34280A/es not_active Application Discontinuation
- 2012-08-21 MY MYPI2013004633A patent/MY180618A/en unknown
- 2012-08-21 US US14/240,045 patent/US9290456B2/en active Active
- 2012-08-21 SI SI201230375T patent/SI2748149T1/sl unknown
- 2012-08-21 EA EA201490471A patent/EA024956B1/ru unknown
- 2012-08-21 BR BR112014003906-2A patent/BR112014003906B1/pt active IP Right Grant
- 2012-08-21 PT PT127531648T patent/PT2748149E/pt unknown
- 2012-08-21 ES ES12753164.8T patent/ES2559631T3/es active Active
- 2012-08-21 CN CN201280040586.3A patent/CN103748079B/zh active Active
- 2012-08-21 JP JP2014526537A patent/JP6022573B2/ja active Active
- 2012-08-21 MX MX2014000783A patent/MX2014000783A/es active IP Right Grant
- 2012-08-21 ME MEP-2016-2A patent/ME02319B/me unknown
- 2012-08-21 KR KR1020147007280A patent/KR101961851B1/ko active IP Right Grant
- 2012-08-21 PL PL12753164T patent/PL2748149T3/pl unknown
- 2012-08-21 AR ARP120103061A patent/AR087607A1/es active IP Right Grant
- 2012-08-21 DK DK12753164.8T patent/DK2748149T5/en active
- 2012-08-21 WO PCT/GB2012/000672 patent/WO2013027000A1/en active Application Filing
- 2012-08-21 AU AU2012298335A patent/AU2012298335B2/en active Active
- 2012-08-21 AP AP2014007512A patent/AP2014007512A0/xx unknown
- 2012-08-22 US US13/591,859 patent/US20130052281A1/en not_active Abandoned
-
2013
- 2013-12-24 IL IL230143A patent/IL230143A/en active IP Right Grant
-
2014
- 2014-01-08 ZA ZA2014/00153A patent/ZA201400153B/en unknown
- 2014-02-17 EC ECSP14013215 patent/ECSP14013215A/es unknown
- 2014-02-17 CL CL2014000395A patent/CL2014000395A1/es unknown
- 2014-02-19 DO DO2014000036A patent/DOP2014000036A/es unknown
- 2014-03-18 CO CO14058009A patent/CO6910197A2/es unknown
- 2014-03-21 CR CR20140133A patent/CR20140133A/es unknown
- 2014-07-23 HK HK14107513.7A patent/HK1194072A1/xx unknown
-
2015
- 2015-12-01 HR HRP20151310TT patent/HRP20151310T2/hr unknown
-
2016
- 2016-01-07 CY CY20161100005T patent/CY1117105T1/el unknown
- 2016-01-21 SM SM201600023T patent/SMT201600023B/it unknown
- 2016-02-03 US US15/014,336 patent/US9931340B2/en active Active
-
2018
- 2018-02-20 US US15/899,561 patent/US10463663B2/en active Active
-
2019
- 2019-09-24 US US16/580,095 patent/US11129828B2/en active Active
-
2021
- 2021-08-30 US US17/461,757 patent/US20220008416A1/en active Pending
-
2022
- 2022-10-06 AR ARP220102738A patent/AR127309A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR127309A2 (es) | Derivados de piridazinona | |
| AR113964A1 (es) | Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa | |
| AR116993A2 (es) | Compuestos heterociclos bicíclicos y sus usos en terapia | |
| AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
| AR106314A1 (es) | COMPUESTOS DE ESPIRO[3H-INDOL-3,2-PIRROLIDIN]-2(1H)-ONA Y DERIVADOS COMO INHIBIDORES DE MDM2 - p53 | |
| AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
| AR078408A1 (es) | Derivados de indol como moduladores de los crac | |
| AR100808A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
| AR086357A1 (es) | Derivados de indazol sustituidos activos como inhibidores de quinasas | |
| AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR090760A1 (es) | Compuestos de benzotiazol y su uso contra el virus de hiv | |
| AR106100A1 (es) | Compuestos bicíclicos como inhibidores duales atx / ca | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR091786A1 (es) | Inhibidores de la produccion de leucotrienos | |
| AR106301A1 (es) | Composiciones de pirrolpirimidina como inhibidores de quinasas | |
| AR100418A1 (es) | Compuestos y composiciones para inducir condrogénesis | |
| AR096846A1 (es) | Dihidroquinoxalinonas y dihidropiridopirazinonas modificadas como inhibidores de la proteína bet | |
| AR091208A1 (es) | Derivados de piperidina | |
| AR099495A1 (es) | Derivados de amida, antagonistas de orexina | |
| AR107054A1 (es) | DERIVADOS DE ISOINDOL Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR RORg Y RORgt | |
| AR087563A1 (es) | Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv) | |
| AR069813A1 (es) | Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento | |
| AR097403A1 (es) | Derivados de benzamida como antagonistas de lpar1 y/o lpar5 y un proceso para su preparación | |
| AR035230A1 (es) | Compuestos de bencimidazol, proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de dicha composicion farmaceutica, y usos de estos compuestos para la elaboracion de medicamentos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |